Molecular targets of the chemopreventive agent 1,4-phenylenebis (methylene)-selenocyanate in human non-small cell lung cancer

Carcinogenesis

Volumn 27, Issue 7, 2006, Pages 1369-1376

  El Bayoumy, Karam ^c   Das, Arunangshu ^c   Narayanan, Bhagavathi ^a   Narayanan, Narayanan ^a   Fiala, Emerich S ^a   Desai, Dhimant ^c   Rao, Chinthalapally V ^b   Amin, Shantu ^c   Sinha, Raghu ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 PHENYLENEBIS(METHYLENE)SELENOCYANATE; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; CYCLIN D1; CYCLOOXYGENASE 2; GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 5; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRON SULFUR PROTEIN; ORGANOSELENIUM DERIVATIVE; PHOSPHOLIPASE A2; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MICROARRAY; DOSE RESPONSE; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; XENOBIOTIC METABOLISM;

ANTIGENS, HUMAN PLATELET; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOPREVENTION; CYCLIN D1; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEIN V-AKT; ORGANOSELENIUM COMPOUNDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33745612975     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi328     Document Type: Article

References (46)

1. International Agency for Research on Cancer. (2004) Tobacco smoke and involuntary smoking. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol. 83, IARC, Lyon.
2. Vineis,P., Alavanja,P., Buffler,E. et al. (2004) Tobacco and cancer: recent epidemiological evidence. J. Natl Cancer Inst., 96, 99-106.
3. Shopland,D.R. (1995) Effect of smoking on the incidence and mortality of lung cancer. In: Johnson,B.E. and Johnson,D.H. (eds), Lung Cancer, John Wiley & Sons, New York, pp. 1-14.
4. Shopland,D.R., Eyre,H.J. and Pechacek,T.F. (1991) Smoking-attributable cancer mortality in 1991: Is lung cancer now the leading cause of death among smokers in the United States? J. Natl Cancer Inst., 83, 1142-1148.
5. Kane,M.A. and Bunn,P.A.Jr (1998) Overview of the biology of lung cancer. In: Kane,M.A. and Bunn,P.A.,Jr (eds), Biology in Health and Disease: Biology of Lung Cancer, Marcel Dekker, pp. 1-9.
6. International Agency for Research on Cancer. (1986) Tobacco smoking. IARC Monogr. Eval. Carcinog. Risks Hum., 38, 421.
7. Marshall,E. (1998) Cancer warriors claim a victory. Science, 279, 1842-1843.
8. Buiatti,E. (1996) Epidemiology of lung cancer. Ann. Inst. Sup. Sanita, 32, 133-144.
9. World Health Organization Geneva (1997) The World Health Report, Conquering suffering enriching humanity, Report of the Director-General, 28-29.
10. De Flora,S., Izzotti,A., D'Agostini,F., Balansky,R.M., Noonan,D. and Albini, A. (2001) Multiple points of intervention in the prevention of cancer and other mutation-related diseases. Mutat. Res., 480-481, 9-22.
11. Kelloff,G.J. (2000) Perspectives on cancer chemoprevention research and drug development. Adv. Cancer Res., 78, 199-334.
12. Hennekens,C.H., Buring,J.E., Manson,J.E. et al. (1996) Lack of effect of long-term supplement with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med., 334, 1145-1149.
13. Omenn,G.S., Goodman,G.E., Thornquist,M.D. et al. (1996) Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial. J. Natl. Cancer Inst., 88, 1550-1559.
14. (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N. Engl. J. Med., 330, 1029-1035.
15. van Zandwijk,N., Dalesio,O., Pastorino,U., de Vries,N. and van Tinteren,H. (2000) EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J. Natl Cancer Inst., 92, 977-986.
16. Clark,L.C., Combs,G.F.Jr, Turnbull,B.W. et al. (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA, 276, 1957-1963.
17. Duffield-Lillico,A.J., Reid,M.E., Turnbull,B.W., Combs,G.F.Jr, Slate,E.H., Fischbach,L.A., Marshall,J.R. and Clark,L.C. (2002) Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial. Cancer Epidemiol. Biomarkers Prev., 11, 630-639.
18. Reid,M.E., Duffield-Lillico,A.J., Garland,L., Turnbull,B.W., Clark,L.C. and Marshall,J.R. (2002) Selenium supplementation and lung cancer incidence: An update of the nutritional prevention of cancer trial. Cancer Epidemiol. Biomarkers Prev., 11, 1285-1291.
19. Bird,S.M., Uden,P.C., Tyson,J.F., Block,E. and Denover,E. (1997) Speciation of seleno-amino acids and organoselenium compounds in selenium enriched yeast using high-performance liquid chromatography-inductively coupled plasma mass spectrometry. J Anal. Atom. Spectrom., 12, 785-788.
20. Rayman,M.P. (2004) The use of high-selenium yeast to raise selenium status: How does it measure up? Br. J. Nutr., 92, 557-573.
21. El-Bayoumy,K., Rose,D.P., Papanikolaou,N., Leszczynska,J., Swamy, M.V. and Rao,C.V. (2002) Cyclooxygenase-2 expression influences growth of human large and small cell lung carcinoma lines in athymic mice: Impact of an organoselenium compound on growth regulation. Int. J. Oncol., 20, 557-561.
22. Sinha,R. and El-Bayoumy,K. (2004) Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr. Cancer Drug Targets, 4, 13-28.
23. Jiang,C., Wang,Z., Ganther,H.E. and Lu,J. (2001) Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostrate cancer cells. Cancer Res., 61, 3062-3070.
24. El-Bayoumy,K., Richie,J.P.Jr, Boyiri,T., Komninou,D., Prokopczyk,B., Trushin,N., Kleinman,W., Cox,J., Pittman,B. and Colosimo,S. (2002) Influence of selenium-enriched yeast supplementation on biomarkers of oxidative damage and hormone status in healthy adult males: A clinical pilot study. Cancer Epidemiol. Biomarkers Prev., 11, 1459-1465.
25. Calvez,F.L., Mukeria,A., Hunt,J.D., Kelm,O., Hung,R.J., Tanière,P., Brennan,P., Boffetta,P., Zaridze,D.G. and Hainaut,P. (2005) TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: Distinct patterns in never, former, and current smokers. Cancer Res., 65, 5076-5083.
26. El-Bayoumy,K., Chae,Y.H., Upadhyaya,P., Meschter,C., Cohen,L.A. and Reddy,B.S. (1992) Inhibition of 7,12-dimethylbenz(a)anthracene-induced tumors and DNA adduct formation in mammary glands of female Sprague-Dawley rats by the synthetic organoselenium compound, 1,4-phenylenebis (methylene)selenocyanate. Cancer Res., 52, 2402-2407.
27. El-Bayoumy,K., Das,A., Boyiri,T., Desai,D., Sinha,R., Pittman,B. and Amin,S. (2003) Comparative action of 1,4-phenylenebis(methylene)selenocyanate and its metaboliates against 7,12-dimethylbenz[a]anthracene-DNA adduct formation in the rat and cell proliferation in rat mammary tumor cells. Chem. Biol. Interact., 146, 179-190.
28. El-Bayoumy,K., Narayanan,B.A., Desai,D.H., Narayanan,N.K., Pittman,B., Amin,S.G., Schwartz,J. and Nixon,D.W. (2003) Elucidation of molecular targets of mammary cancer chemoprevention in the rat by organoselenium compounds using cDNA microarray. Carcinogenesis, 24, 1505-1514.
29. Das,A., Desai,D., Pittman,B., Amin,S. and El-Bayoumy,K. (2003) Comparison of the chemopreventive efficacies of 1,4-phenylenebis(methylene) selenocyanate and selenium-enriched yeast on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mouse. Nutr. Cancer, 46, 179-185.
30. Rosa,J.G., Prokopczyk,B., Desai,D.H., Amin,S.G. and El-Bayoumy,K. (1998) Elevated 8-hydroxy-2′-deoxyguanosine levels in lung DNA of A/J mice and F344 rats treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and inhibition by dietary 1,4-phenylenebis(methylene)selenocyanate. Carcinogenesis, 19, 1783-1788.
31. Brown,J.R. and DuBois,R.N. (2004) Cyclooxygenase as a target in lung cancer. Cancer Res., 10, 4266-4269.
32. Harris,R.E., Beebe-Donk,J., Doss,H. and Burr Doss,D. (2005) Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade. Oncol. Rep., 13, 559-583.
33. Soriano,A.F., Helfrich,B., Chan,D.C., Heasley,L.E., Bunn,P.A.Jr and Chou,T.C. (1999) Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res., 59, 6178-6184.
34. Brognard,J., Clark,A.S., Ni,Y. and Dennis,P.A. (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res., 61, 3986-3997.
35. West,K.A., Linnoila,I.R., Belinsky,S.A., Harris,C.C. and Dennis,P.A. (2004) Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3′-kinase/Akt pathway in vitro and in vivo. Cancer Res., 64, 446-451.
36. Yang,L., Dan,H.C., Sun,M. et al. (2004) Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res., 64, 4394-4399.
37. Hoffman,D., Hoffman,I. and El-Bayoumy,K. (2001) The less harmful cigarette: A controversial issue, a tribute to Ernst L. Wynder. Chem. Res. Toxicol., 14, 767-790.
38. West,K.A., Brognard,J., Clark,A.S., Linnoila,I.R., Yang,X., Swain,S.M., Harris,C., Belinsky,S. and Dennis,P.A. (2003) Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J. Clin. Invest., 111, 81-90.
39. Davis,C.D. and Milner,J. (2004) Frontiers in nutrigenomics, proteomics, metabolomics and cancer prevention. Mutat. Res., 551, 51-64.
40. El-Bayoumy,K. and Sinha,R. (2005) Molecular chemoprevention by selenium: a genomic approach. Mutat. Res., 591, 224-236.
41. Sabourin,C.L., Wang,Q.S., Ralston,S.L. et al. (1998) Expression of cell cycle proteins in 4-(methylnitrosamino)-1(3-pyridyl)-1-butanone-induced mouse lung tumors. Exp. Lung Res., 24, 499-521.
42. Shishodia,S. and Aggarwal,B.B. (2004) Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-κB by suppressing activation of IκBα kinase in human non-small cell lung carcinoma: Correlation with suppression of cyclin D1, COX-2 and matrix metalloproteinase-9. Cancer Res., 64, 5004-5012.
43. Weinstein,I.B. (2000) Disorders in cell circuitry during multistage carcinogenesis: The role of homeostasis. Carcinogenesis, 21, 857-864.
44. 1-to-S-phase transition. Mol. Cell. Biol., 19, 2690-2698.
45. Karin,M., Cao,Y., Greten,F.R. and Li,Z-W. (2002) NF-κB in cancer: From innocent bystander to major culprit. Nat. Rev., 2, 301-309.
46. Miura,K., Bowman,E.D., Simon,R. et al. (2002) Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking-and prognosis-related molecular profiles. Cancer Res., 62, 3244-3250.